Patents by Inventor Michael D. Waterfield

Michael D. Waterfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for determining expression of a PI3 kinase gene
    Patent number: 7422849
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 9, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Polypeptides having kinase activity, their preparation and use
    Patent number: 6274327
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: May 27, 1998
    Date of Patent: August 14, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Polypeptides having kinase activity, their preparation and use
    Patent number: 5846824
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: January 9, 1997
    Date of Patent: December 8, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Polypeptides having kinase activity, their preparation and use
    Patent number: 5824492
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: October 20, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Schwann cell mitogenic factor, its preparation and use
    Patent number: 5594114
    Abstract: The invention provides a new Schwann cell-mitogenic factor of molecular weight about 43 to 45 kilodaltons, when isolated by SDS-PAGE. The invention provides therapeutic formulation comprising the new factor, and the use of the factor and the said formulations in treating conditions which involve a factor-sensitive or factor-responsive cell type.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: January 14, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Andrew D. J. Goodearl, Paul Stroobant, Michael D. Waterfield
  • Method of detecting truncated epidermal growth factor receptors
    Patent number: 4933294
    Abstract: Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumor explant cells, for structurally altered or abnormally expressed growth factor receptors or for the RNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also described.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: June 12, 1990
    Assignees: ICRF Patents Limited, Research & Development Co., Ltd. Yeda, Genentech, Inc.
    Inventors: Michael D. Waterfield, J. Schlessinger, Axel Ullrich